Fiche centre
Ottawa Hospital Research Institute
Ottawa — Canada
Essais liés7clinical trials
VilleOttawalocalisation
PaysCanadalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06249867
Essais cliniques associés
7| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| BIA 28-6156 10 mg | Parkinson | Phase 2 | NCT05819359 | ACTIVATE — Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD | COMPLETED |
| Tenecteplase | Accident vasculaire cérébral | Phase 3 | NCT06320431 | ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632 | RECRUITING |
| Recombinant Factor VIIa | Accident vasculaire cérébral | Phase 3 | NCT07227246 | FASTEST Part 2 — Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2 | RECRUITING |
| BB-031 | Accident vasculaire cérébral | Phase 2 | NCT06226805 | Study of BB-031 in Acute Ischemic Stroke Patients (RAISE) | RECRUITING |
| Darifenacin 7.5 MG Extended Release Oral Tablet | Sclérose latérale amyotrophique | Phase 2 | NCT06249867 | A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALS | RECRUITING |
| AIDP — Automated Imaging Differentiation of Parkinsonism | Parkinson | À vérifier | NCT05913687 | AIDP — Automated Imaging Differentiation of Parkinsonism | ACTIVE_NOT_RECRUITING |
| Efgartigimod PH20 SC | Myasthénie | Phase 3 | NCT06558279 | ADAPT oculus — A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis | ACTIVE_NOT_RECRUITING |